We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current NGNE market cap is 252.53M. The company's latest EPS is USD -2.4448 and P/E is -6.91.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 925k | 0 |
| Operating Income | -5.57M | -31.82M | -18.78M | -20.13M | -22.18M |
| Net Income | -4.53M | -15.5M | -16.92M | -18.49M | -20.22M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 7.83M | 0 | 0 | 0 |
| Operating Income | -70.96M | -33.73M | -60.7M | -59.1M | -55.58M |
| Net Income | -69.44M | -33.28M | -60.69M | -57.56M | -36.32M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 89.59M | 222.57M | 195.35M | 179.82M | 164.12M |
| Total Liabilities | 14.35M | 36.55M | 24.57M | 24.81M | 26.71M |
| Total Equity | 75.24M | 186.02M | 170.78M | 155.01M | 137.41M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 147.02M | 210.52M | 163.26M | 115.95M | 222.57M |
| Total Liabilities | 5.34M | 19.3M | 20.4M | 21.62M | 36.55M |
| Total Equity | 141.69M | 191.22M | 142.86M | 94.33M | 186.02M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -21.35M | -51.42M | -21.65M | -37.54M | -53.11M |
| Investing | 8.68M | 25.64M | 29.94M | 6.32M | -22.65M |
| Financing | -361k | 92.48M | -6.52M | -6.13M | -5.99M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -15.39M | -24.58M | -47.56M | -45.61M | -51.42M |
| Investing | -688k | -2.22M | -3.26M | -59.13M | 25.64M |
| Financing | 82.24M | 77.14M | 732k | 161k | 92.48M |
| Market Cap | 252.53M |
| Price to Earnings Ratio | -6.91 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.69 |
| Price to Book Ratio | 1.35 |
| Dividend Yield | - |
| Shares Outstanding | 14.85M |
| Average Volume (1 week) | 215.93k |
| Average Volume (1 Month) | 165.8k |
| 52 Week Change | -54.37% |
| 52 Week High | 74.49 |
| 52 Week Low | 14.42 |
| Spread (Intraday) | 0.08 (0.47%) |
| Company Name | Neurogene Inc |
| Address |
corporation trust center 1209 orange st wilmington, delaware 19802 |
| Website | https://www.neoleukin.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
